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Exposure to particulate matter (PM) air pollu-
tion is associated with increased respiratory
and cardiovascular morbidity and mortality
(Peters et al. 2000, 2001a; Pope et al. 2004).
Plausible mechanisms explaining the cardio-
vascular effects of particle exposure have not
been clearly defined (Utell et al. 2002).
However, recent studies provide evidence that
PM exposure is associated with systemic
inflammation and changes in vascular func-
tion that have been implicated in the patho-
physiology of cardiovascular disease, providing
clues to possible mechanisms. PM exposure
has been associated with increased systolic
blood pressure (Ibald-Mulli et al. 2001),
plasma viscosity (Peters et al. 1997a), C-reac-
tive protein (Peters et al. 2001b), ﬁbrinogen
(Pekkanen et al. 2000), and release of leuko-
cytes from the bone marrow (Mukae et al.
2001; Tan et al. 2000). Increases in ambient
concentrations of PM were associated with
increased blood leukocyte and platelet counts,
as well as ﬁbrinogen (Schwartz 2001). Brook
et al. (2002) found evidence for systemic
vasoconstriction in resting human subjects
exposed to concentrated ambient air particles
and ozone.
Ultraﬁne particles (UFPs), deﬁned as par-
ticles with a diameter < 100 nm, have been
hypothesized as contributors to cardiovascular
effects of PM (Seaton et al. 1995) because,
compared with fine particles at similar mass
concentrations, they have greater pulmonary
deposition efficiency (Chalupa et al. 2004;
Daigle et al. 2003), induce more pulmonary
inflammation (Li et al. 1999; Oberdörster
et al. 1995), have enhanced oxidant capacity
(Brown et al. 2001; Li et al. 2003), have a
higher propensity to penetrate the epithelium
and reach interstitial sites (Stearns et al. 1994),
and may even enter the systemic circulation in
humans (Nemmar et al. 2002; Oberdörster
et al. 2002).
Relatively few epidemiologic studies have
examined the health effects of UFP exposure
because most ambient air monitoring measures
particle mass, and there is relatively poor cor-
relation between particle mass (dominated by
ﬁne particles) and particle number (dominated
by UFPs). However, a recent study in Erfurt,
Germany, found associations between ambient
UFPs and mortality (Wichmann et al. 2000).
In a study of patients with stable coronary
artery disease (Pekkanen et al. 2002), investiga-
tors performed repeated exercise tests concur-
rent with monitoring of ambient particle mass
and number counts. Signiﬁcant independent
effects were found for both ﬁne particles and
UFPs on the degree of ST-segment depression
on the electrocardiogram during exercise.
Asthma, a disease characterized by airway
inﬂammation, confers an increased risk for PM
health effects (Atkinson et al. 2001; Lipsett
et al. 1997; Tolbert et al. 2000). There is evi-
dence for activation of lung leukocytes and pul-
monary vascular endothelium in subjects with
asthma, particularly during exacerbations
(Ohkawara et al. 1995). Activation of T-lym-
phocytes with production of “type 2” inﬂam-
matory cytokines drives the recruitment and
retention of eosinophils in the airway, which
contribute to the chronic epithelial injury char-
acteristic of this disease (Corrigan and Kay
1990; Wilson et al. 1992). Treatment with
inhaled corticosteroids reduces expression of
activation markers CD25 and human leuko-
cyte antigen (HLA)-DR in lung lymphocytes
and also reduces HLA-DR expression in
blood lymphocytes (Wilson et al. 1994). In
asthma, blood CD4+ T cells express increased
mRNA for interleukin (IL)-4, IL-5, and gran-
ulocyte macrophage colony stimulating factor,
and IL-5 mRNA expression correlates with
asthma severity and eosinophilia (Corrigan
et al. 1995). Allergen challenge in subjects
with asthma causes a reduction in blood
CD4+ T cells (Walker et al. 1992) and an
increase in airway CD4+ cells (Virchow et al.
1995). UFP exposure may worsen asthma
by further shifting lymphocyte responses to
the type 2 phenotype, by further activating
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Ultraﬁne particles (UFPs; aerodynamic diameter < 100 nm) may contribute to the respiratory and
cardiovascular morbidity and mortality associated with particulate air pollution. We tested the
hypothesis that inhalation of carbon UFPs has vascular effects in healthy and asthmatic subjects,
detectable as alterations in blood leukocyte expression of adhesion molecules. Healthy subjects
inhaled filtered air and freshly generated elemental carbon particles (count median diameter
~ 25 nm, geometric standard deviation ~ 1.6), for 2 hr, in three separate protocols: 10 µg/m3 at
rest, 10 and 25 µg/m3 with exercise, and 50 µg/m3 with exercise. In a fourth protocol, subjects with
asthma inhaled air and 10 µg/m3 UFPs with exercise. Peripheral venous blood was obtained before
and at intervals after exposure, and leukocyte expression of surface markers was quantitated using
multiparameter ﬂow cytometry. In healthy subjects, particle exposure with exercise reduced expres-
sion of adhesion molecules CD54 and CD18 on monocytes and CD18 and CD49d on granulo-
cytes. There were also concentration-related reductions in blood monocytes, basophils, and
eosinophils and increased lymphocyte expression of the activation marker CD25. In subjects with
asthma, exposure with exercise to 10 µg/m3 UFPs reduced expression of CD11b on monocytes and
eosinophils and CD54 on granulocytes. Particle exposure also reduced the percentage of CD4+
T cells, basophils, and eosinophils. Inhalation of elemental carbon UFPs alters peripheral blood
leukocyte distribution and expression of adhesion molecules, in a pattern consistent with increased
retention of leukocytes in the pulmonary vascular bed. Key words: blood leukocytes, human, mono-
cytes, ultraﬁne particles. Environ Health Perspect 114:51–58 (2006). doi:10.1289/ehp.7962 avail-
able via http://dx.doi.org/ [Online 20 September 2005]resident lymphocytes, by increasing the likeli-
hood that lymphocytes will encounter antigen,
and/or by increasing penetration of allergen
through an injured epithelium.
We have initiated controlled exposure
studies with carbon UFPs in humans, as a sur-
rogate for environmental UFPs, demonstrating
that UFPs have a high pulmonary deposition
efficiency in healthy subjects (Daigle et al.
2003), which is further increased in subjects
with asthma (Chalupa et al. 2004). Exposure
to 50 µg/m3 carbon UFPs caused a reduction
in the pulmonary diffusing capacity for carbon
monoxide (Pietropaoli et al. 2004b) associated
with reductions in the systemic vascular
response to increased flow (Pietropaoli et al.
2004a), without significant effects on symp-
toms, airway inﬂammation, lung function, or
markers of blood coagulation (Pietropaoli et al.
2004c). We hypothesized that inhalation of
UFPs alters vascular function, detectable as
alterations in blood leukocyte distribution,
activation, and expression of adhesion mole-
cules. We further hypothesized that people
with asthma, who have airway and systemic
inﬂammation at baseline as well as enhanced
UFP deposition, have enhanced susceptibility
to these vascular effects. In this article we pre-
sent detailed analyses of venous blood leuko-
cytes from subjects participating in four
separate studies involving carbon UFP expo-
sure: three protocols with varying exposure
concentrations in healthy subjects, and one
protocol with asthmatic subjects. Some data in
this article have been presented previously in
abstract form (Frampton et al. 2004).
Materials and Methods
Subjects. Written, informed consent was
obtained from all subjects, and the studies
were approved by the Research Subjects
Review Board of the University of Rochester.
Fifty-six never-smoking subjects 18–40 years
of age (40 healthy and 16 with asthma) par-
ticipated and were paid a stipend. Subjects
were not studied within 6 weeks of a respira-
tory infection. Healthy subjects were required
to have normal spirometry, a normal 12-lead
electrocardiogram, and no history of chronic
respiratory disease.
Inclusion criteria for subjects with asthma
have been reported previously (Chalupa et al.
2004). These criteria included a consistent
clinical history, and either a significant
bronchodilator response or airway hyper-
responsiveness to methacholine. The severity
was consistent with mild intermittent to mod-
erate persistent asthma (National Institutes of
Health 1997). Subjects with forced expiratory
volume in 1 sec (FEV1) < 70% of predicted at
baseline screening, or with > 20% reduction
in FEV1 after the screening exercise, were
excluded.
Study design. Each study used a crossover
design in which each subject was exposed to
ﬁltered air and to UFPs, so that each subject
served as his or her own control. Within each
study, the order of air/UFP exposure was ran-
domized, and the randomization was blocked
by order of presentation and sex, so that equal
numbers of men and women inhaled air ﬁrst
or UFPs ﬁrst. Exposures were blinded to both
subjects and investigators.
Table 1 provides details of each study
protocol. The ﬁrst, UPREST, involved 12 (six
female) subjects exposed at rest to approxi-
mately 10 µg/m3 UFPs or ﬁltered air for 2 hr.
The second study protocol, UPDOSE,
involved 12 subjects (six female) with three
2-hr exposures with exercise for each subject:
approximately 10 µg/m3 UFPs, approximately
25 µg/m3 UFPs, and ﬁltered air. Subjects exer-
cised on a bicycle ergometer for 15 min of each
half hour at an intensity adjusted to increase
the minute ventilation to approximately
20 L/min/m2 body surface area. For safety
reasons, the order of exposure was randomized
in a restricted fashion, so that each subject
received the 10-µg/m3 exposure before the
25-µg/m3. The third protocol, UP50, involved
16 healthy subjects (eight female) exposed to
approximately 50 µg/m3 UFPs and air for 2 hr,
with intermittent exercise as in the UPDOSE
protocol. The final protocol, UPASTHMA,
involved 16 subjects with asthma (eight
female) exposed to approximately 10 µg/m3
UFPs and air for 2 hr, with intermittent exer-
cise as in the UPDOSE protocol. All exposures
were separated by at least 2 weeks.
Exposures to either ﬁltered air or UFPs were
administered by mouthpiece (with nose clip) for
2 hr, interrupted by a 10-min break after the
ﬁrst hour. Before and at 0, 3.5, and 21 hr after
exposure, blood pressure, heart rate, and oxygen
saturation by pulse oximetry were measured,
and blood was drawn from an antecubital vein.
For UP50 and UPASTHMA, measurements
were also obtained 45 hr after exposure.
Exposure system. The rationale and design
of the exposure facility have been described in
detail elsewhere (Chalupa et al. 2002). Brieﬂy,
particles [count median diameter ~ 25 nm,
geometric standard deviation ~ 1.6] were gen-
erated in an argon atmosphere using an elec-
tric spark discharge between two graphite
electrodes, and then deionized and diluted
with ﬁltered air to the desired concentration.
Particle number, mass, and size distribution
were monitored on both the inspiratory and
expiratory sides of the subject. Electronic inte-
gration of a pneumotachograph signal pro-
vided tidal volume, respiratory frequency, and
minute ventilation measurements. Air for the
control exposures, and for dilution of the par-
ticles, was passed through charcoal and high-
efficiency particle filters and was essentially
free of particles (0–10 particles/cm3).
Blood leukocyte immunofluorescence
analysis. Fresh heparinized whole blood was
stained with three monoclonal antibodies: the
marker of interest (Table 2) conjugated to ﬂu-
orescein isothiocyanate, CD14 conjugated to
phycoerythrin, and CD45 conjugated to
pericidin chlorophyll protein. This permitted
determination of the relative expression of
adhesion molecules and other markers sepa-
rately on polymorphonuclear leukocytes
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Table 1. Study design (mean ± SD).
UPREST UPDOSE UP50 UPASTHMA
No. of subjects 12 12 16 16
Subject age (years) 30.1 ± 8.9 26.9 ± 5.8 26.9 ± 6.5 23.0 ± 2.7
FEV1 (% predicted) 103.8 ± 8.0 106.3 ± 16.6 102.8 ± 9.5 97.6 ± 5.0
Nominalaparticle mass (µg/m3) 0, 10 0, 10, 25 0, 50 0, 10
Rest/exercise Rest Intermittent exercise Intermittent exercise Intermittent exercise
aThe target mass concentration of UFPs for each protocol.
Table 2. Leukocyte markers measured in each protocol.
Cluster designation Name Source (clone) Description
CD3 BD Biosciencea (SK7) Marker of T-lymphocytes
CD4 BD Bioscience (SK3) Marker of T-helper lymphocytes
CD8 BD Bioscience (SK1) Marker of T-cytotoxic lymphocytes
CD11a Leukocyte function GenTrakb (38) or Part of β2 integrin adhesion molecule complex
antigen-1 Coulterc (25.3.1)
CD11b Mac-1 Ancelld (ICRF44) Subunit of complement receptor 3, part of β2
integrin adhesion molecule complex
CD18e Pharmigena (6.7) or Part of β2 adhesion molecule complex with
BD Bioscience (L130) CD11a and CD11b
CD25 Tac BD Bioscience (2A3) Epitope of IL-2 receptor, activation marker on
lymphocytes
CD49d Very late antigen-α4 Serotecf (44H6) Part of β1 integrin adhesion molecule complex
CD54 Intercellular adhesion Southern Biotechnologyg Adhesion molecule
molecule-1 (15.2)
CD62L L-selectin Coulter (DREG56) or Adhesion molecule
Pharmigen (DREG56)
aSan Jose, CA. bPlymouth Meeting, PA. cMiami, FL. dBayport, MN. eMeasured in UP50 and UPASTHMA only. fRaleigh, NC.
gBirmingham, AL.(PMNs), eosinophils, lymphocytes, and
monocytes. The appropriate isotype control
antibodies were run with each experiment to
assist in appropriate gate setting. The adhe-
sion markers shown in Table 2 were meas-
ured in each of the study protocols, except for
CD18, which was measured in UP50 and
UPASTHMA only.
Red blood cells were lysed and cells were
analyzed on a FACScan ﬂow cytometer (BD
Bioscience, San Jose, CA) equipped with a
15-mW argon ion laser emitting at 488 nm.
Ten thousand events were collected from each
sample in list mode. Standardized ﬂuorescent
microbeads (Quantium 24P and 25P; Bangs
Laboratories, Fishers, IN) were run with each
experiment to convert mean channel numbers
to molecules of equivalent soluble fluoro-
chrome (MESF) (Gavras et al. 1994). This
provided a correction for minor day-to-day
instrument variations in ﬂuorescence detection.
Total and differential blood leukocyte and
platelet counts were performed in the clinical
laboratories of Strong Memorial Hospital,
using an automated analyzer (Celldyne 4000;
Abott Laboratories, Santa Clara, CA).
Data handling and statistical methods.
Data were entered on a desktop computer
using Microsoft Excel and analyzed using SAS
(SAS Institute Inc., Cary, NC).
UPREST, UPASTHMA, and UP50 used
a standard, two-period crossover design in
which each subject received both particles and
air. Equal numbers of males and females were
included. The order of presentation was ran-
domized separately for each sex, with half of
each group of subjects receiving each of the
two possible orders. UPDOSE used a three-
period crossover design in which each subject
received air and both 10-µg/m3 and 25-µg/m3
concentrations of particles. There were then
three possible exposure sequences, depending
on where in the sequence the air exposure was
placed. Equal numbers of subjects were ran-
domly assigned to each sequence.
Repeated-measures analysis of variance
(ANOVA) was used (Wallenstein and Fisher
1977), with order of presentation as a
between-subjects factor, with exposure and
time as within-subject factors. The analysis
included tests for period and carryover effects,
although the latter were expected to be mini-
mal because of the nature of the exposures and
the length of the washout period. In cases
where carryover effects were signiﬁcant, ﬁrst-
period data were examined separately (Jones
and Kenward 1989). Each ANOVA included
an examination of residuals as a check on the
required assumptions of normally distributed
errors with constant variance. If these assump-
tions were not satisﬁed, data transformations
(e.g., square-root transformation for cell
counts) were considered. A p-value of 0.05
was required for statistical signiﬁcance. Data
are shown as mean ± SE, unless otherwise
indicated.
Results
Exposure data and subject characteristics.
Table 3 shows the exposure parameters and
subject characteristics for each protocol. Most
of the subjects with asthma were atopic (15 of
16), and most (11 of 16) were not on inhaled
steroids, long-acting bronchodilators, or
leukotriene inhibitors. All subjects completed
every exposure; men and women did not differ
in the achieved minute ventilation, adjusted for
body surface area. There were no significant
effects of UFP exposure on ventilatory parame-
ters or pulmonary function; these results, and
UFP deposition, have been published previ-
ously (Daigle et al. 2003).
The UPREST protocol, with exposures at
rest to 10 µg/m3 UFPs, showed no convincing
differences between particle and air exposure
for leukocyte expression of adhesion molecules
or total and differential leukocyte counts.
There were rare statistically signiﬁcant compari-
sons, but the signiﬁcance levels were modest,
and the data did not suggest a consistent bio-
logic response. Overall, exposure to 10 µg/m3
UFPs at rest had no signiﬁcant effects on blood
leukocytes.
Findings from the three studies involving
exercise are described below.
Blood leukocyte expression of adhesion mol-
ecules. In these studies, quantitative surface
expression of molecules that mediate leukocyte-
endothelial interactions served as an indirect
indicator of exposure effects on pulmonary vas-
cular endothelial function. The use of flow
cytometry with calibrated fluorescent beads
allowed quantitation of small changes in surface
marker density. Adhesion molecule expression
for monocytes and PMNs in the three proto-
cols involving exercise is shown in Tables 4–6.
UPDOSE. UFP exposure caused a con-
centration-related reduction in monocyte
expression of CD54 [intercellular adhesion
molecule-1 (ICAM-1) (exposure effect,
Ultrafine particles and blood leukocytes
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Table 3. Exposure parameters (mean ± SD).
UPREST UPDOSE UPDOSE UP50 UPASTHMA
Nominal particle mass (µg/m3)1 01 02 55 01 0
Measured particle mass (µg/m3) 10.00 ± 2.14 13.87 ± 4.02 28.46 ± 5.13 49.97 ± 3.88 11.08 ± 3.11
Particle number (× 106 particles/cm3) 1.88 ± 0.09 2.04 ± 0.07 6.96 ± 0.10 10.79 ± 1.66 2.20 ± 0.10
CMD (nm) 27.3 ± 2.5 25.2 ± 1.7 26.5 ± 1.5 27.9 ± 2.2 23.1 ± 1.6
GSD 1.62 ± 0.02 1.60 ± 0.02 1.60 ± 0.02 1.65 ± 0.02 1.64 ± 0.01
Abbreviations: CMD, count median diameter; GSD, geometric standard deviation.
Table 4. Adhesion molecule expression on monocytes and PMNs, UPDOSE protocol (mean ± SE, MESF).
Exposure
(µg/m3) Baseline 0 hr 3.5 hr 21 hr ANOVA
Monocytes
CD11a Air 64,429 ± 2,072 62,483 ± 2,140 62,571 ± 1,689 65,682 ± 2,435
UFP 10 63,818 ± 4,109 59,900 ± 2,493 59,190 ± 3,063 65,249 ± 2,518
UFP 25 62,835 ± 2,644 56,207 ± 5,436 59,635 ± 2,404 63,008 ± 2,126
CD11b Air 19,034 ± 986 19,497 ± 997 21,076 ± 1,653 20,901 ± 1,912
UFP 10 17,632 ± 990 17,287 ± 1,171 18,335 ± 1,501 19,391 ± 1,185
UFP 25 19,056 ± 1,214 17,769 ± 922 22,059 ± 4,697 22,669 ± 3,357
CD49d Air 14,222 ± 1,000 13,562 ± 854 13,717 ± 880 13,989 ± 964
UFP 10 13,634 ± 1,029 12,587 ± 694 12,946 ± 706 13,059 ± 797
UFP 25 13,590 ± 839 12,779 ± 574 12,372 ± 683 13,542 ± 935
CD54 Air 12,188 ± 319 13,096 ± 519 13,908 ± 645 13,307 ± 823 Exposure
UFP 10 12,541 ± 469 12,470 ± 583 12,855 ± 592 13,110 ± 781 p = 0.001
UFP 25 13,717 ± 686 12,591 ± 584 13,533 ± 856 14,482 ± 991
CD62L Air 43,970 ± 3,212 34,937 ± 3,519 37,600 ± 3,391 37,399 ± 3,716 Exposure × sex
UFP 10 38,953 ± 3,465 30,281 ± 2,510 32,409 ± 1,719 36,356 ± 3,207 p = 0.006
UFP 25 41,357 ± 4,453 33,134 ± 2,940 34,676 ± 3,234 39,168 ± 4,196
PMNs
CD11a Air 28,637 ± 1,073 28,613 ± 1,228 28,793 ± 1,183 28,867 ± 1,503
UFP 10 29,124 ± 1,073 26,216 ± 1,160 26,260 ± 985 27,620 ± 923
UFP 25 28,444 ± 1,397 27,939 ± 1,151 27,817 ± 1,137 27,157 ± 1,411
CD11b Air 18,467 ± 1,117 18,837 ± 1,223 21,427 ± 3,186 21,189 ± 2,383
UFP 10 16,728 ± 907 15,997 ± 1,175 16,049 ± 1,112 21,169 ± 2,394
UFP 25 19,778 ± 2,671 15,671 ± 1,179 20,461 ± 3,457 18,653 ± 1,760
CD49d Air 7,422 ± 593 6,572 ± 542 6,404 ± 498 6,098 ± 686 Exposure × sex
UFP 10 7,007 ± 561 6,172 ± 559 6,173 ± 423 6,340 ± 650 p = 0.007
UFP 25 6,681 ± 465 6,031 ± 442 5,677 ± 446 5,925 ± 470
CD54 Air 4,792 ± 279 4,500 ± 280 4,586 ± 246 4,457 ± 243
UFP 10 4,953 ± 271 4,292 ± 242 4,608 ± 424 4,435 ± 213
UFP 25 4,771 ± 321 4,084 ± 216 4,122 ± 215 4,417 ± 230
CD62L Air 66,179 ± 3,910 59,419 ± 4,413 64,867 ± 4,303 59,671 ± 5,970
UFP 10 60,976 ± 4,340 57,202 ± 4,515 56,621 ± 4,636 60,626 ± 4,180
UFP 25 66,145 ± 4,231 60,044 ± 5,434 59,625 ± 4,296 61,184 ± 4,054p = 0.0012); Figure 1]. Expression increased
after exposure to filtered air and decreased
with 25 µg/m3 UFPs, with differences resolv-
ing by 21 hr after exposure. Expression of
CD62L showed a significant exposure–sex
interaction (p = 0.0006; data not shown),
with expression increasing in females but
decreasing in males relative to air exposure.
However, these findings lacked a clear con-
centration response.
UP50. Exposure to 50 µg/m3 UFPs also
reduced expression of CD54 on monocytes
(Figure 2A,B), but to a greater extent in males
(exposure–sex interaction, p = 0.025). The
percentage of monocytes expressing CD54
was also reduced (p = 0.035; data not shown).
UFP exposure persistently blunted the air-
related increase in CD18 expression on mono-
cytes (p = 0.0002; Figure 2C). Expression of
CD18 was also reduced on PMNs (Figure
2D), and ANOVA indicated significantly
increased CD11a expression on PMNs (expo-
sure–time interaction, p = 0.037; data not
shown).
UPASTHMA. As expected, we found base-
line differences between healthy and asthmatic
subjects in leukocyte expression of adhesion
molecules; these data are shown in Table 7.
For example, monocyte expression of CD11b,
CD54, and CD62L was higher in subjects
with asthma than in healthy subjects.
In subjects with asthma, exposure to
10 µg/m3 UFPs reduced expression of CD11b
on blood monocytes (p = 0.029; Figure 3A)
and also reduced expression on eosinophils
(p = 0.015; Figure 3B). Expression of CD62L
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Table 5. Adhesion molecule expression on monocytes and PMNs, UP50 protocol (mean ± SE, MESF).
Exposure Baseline 0 hr 3.5 hr 21 hr 45 hr ANOVA
Monocytes
CD11a Air 65,882 ± 3,277 66,463 ± 2,934 65,658 ± 2,963 69,888 ± 2,853 71,292 ± 2,885
UFP 69,090 ± 3,146 68,680 ± 2,935 66,222 ± 2,696 69,813 ± 2,835 71,773 ± 3,132
CD11b Air 16,840 ± 899 20,104 ± 905 19,938 ± 835 18,728 ± 1,092 18,364 ± 993
UFP 18,365 ± 1,153 19,733 ± 1,206 18,531 ± 952 18,389 ± 932 18,369 ± 815
CD18 Air 62,675 ± 2,948 68,897 ± 2,942 67,872 ± 2,780 68,661 ± 2,749 68,963 ± 3,187 Exposure
UFP 67,246 ± 2,751 67,175 ± 2,582 66,277 ± 2,488 67,307 ± 2,768 68,754 ± 3,052 p = 0.0002
CD49d Air 16,334 ± 939 16,588 ± 859 17,371 ± 954 16,951 ± 9,571 17,126 ± 1,079
UFP 16,643 ± 938 16,445 ± 874 17,182 ± 965 17,282 ± 909 17,484 ± 1,167
CD54 Air 9,637 ± 1,431 10,654 ± 1,668 11,198 ± 1,728 9,969 ± 1,639 9,827 ± 1,687 Exposure ×sex
UFP 10,526 ± 1,715 11,095 ± 1,782 10,889 ± 1,871 10,352 ± 1,791 10,339 ± 1,811 p = 0.025
CD62L Air 58,551 ± 3,188 50,197 ± 3,410 48,580 ± 3,027 9,699 ± 1,557 59,189 ± 2,271
UFP 57,666 ± 3,519 49,307 ± 3,261 50,241 ± 2,848 56,880 ± 3,515 58,283 ± 3,020
PMNs
CD11a Air 30,921 ± 851 30,934 ± 862 31,339 ± 960 31,683 ± 944 31,712 ± 937 Exposure × time
UFP 31,569 ± 1,014 32,158 ± 1,055 31,652 ± 912 31,751 ± 927 32,130 ± 921 p = 0.037
CD11b Air 16,406 ± 628 18,053 ± 934 17,262 ± 678 17,355 ± 869 17,525 ± 848
UFP 16,678 ± 830 19,155 ± 1,953 17,076 ± 777 18,014 ± 713 17,545 ± 694
CD18 Air 34,919 ± 1,335 36,961 ± 1,352 36,486 ± 1,286 35,907 ± 1,226 35,868 ± 1,450 Exposure
UFP 36,010 ± 1,032 37,687 ± 1,810 36,255 ± 1,060 35,316 ± 983 35,682 ± 1,087 p = 0.023
CD49d Air 6,455 ± 412 6,345 ± 264 6,399 ± 279 6,145 ± 204 6,070 ± 203
UFP 6,186 ± 335 6,252 ± 330 6,362 ± 340 6,284 ± 305 6,114 ± 258
CD54 Air 8,182 ± 584 8,339 ± 484 8,973 ± 552 8,114 ± 415 8,072 ± 383
UFP 8,524 ± 427 9,071 ± 545 8,668 ± 458 8,501 ± 402 8,446 ± 389
CD62L Air 87,437 ± 4,510 88,596 ± 3,485 88,617 ± 4,056 87,244 ± 3,362 89,489 ± 2,648
UFP 92,053 ± 4,760 89,783 ± 4,262 90,736 ± 4,227 89,363 ± 3,898 94,055 ± 4,598
Table 6. Adhesion molecule expression on monocytes and PMNs, UPASTHMA protocol (mean ± SE, MESF).
Exposure Baseline 0 hr 3.5 hr 21 hr 45 hr ANOVA
Monocytes
CD11a Air 21,179 ± 4,120 20,442 ± 3,989 19,336 ± 4,042 21,126 ± 5,569 21,407 ± 5,550
UFP 32,102 ± 7,076 30,277 ± 6,791 29,592 ± 6,630 30,468 ± 6,809 29,751 ± 6,640
CD11b Air 25,022 ± 2,822 31,626 ± 5,969 26,553 ± 3,319 26,345 ± 3,456 27,703 ± 3,228 Exposure
UFP 26,958 ± 4,112 25,452 ± 4,611 25,742 ± 4,241 24,498 ± 4,199 25,814 ± 3,502 p = 0.029
CD18 Air 85,586 ± 6,773 87,234 ± 8,882 82,899 ± 6,465 82,697 ± 7,370 85,455 ± 7,819
UFP 84,999 ± 7,252 81,131 ± 7,931 81,297 ± 9,950 82,028 ± 6,767 77,346 ± 7,334
CD49d Air 17,172 ± 731 16,739 ± 925 16,013 ± 616 16,627 ± 837 16,856 ± 771
UFP 18,378 ± 865 16,967 ± 873 17,138 ± 919 17,715 ± 877 17,327 ± 879
CD54 Air 19,102 ± 1,386 19,432 ± 1,430 18,285 ± 1,248 19,043 ± 1,410 19,281 ± 1,319
UFP 20,673 ± 2,009 20,438 ± 2,088 19,861 ± 1,934 20,014 ± 1,853 19,284 ± 1,491
CD62L Air 45,571 ± 2,571 39,446 ± 2,652 41,214 ± 2,703 45,100 ± 2,847 44,329 ± 2,870
UFP 51,939 ± 5,305 43,483 ± 4,955 42,198 ± 3,954 46,105 ± 4,023 45,608 ± 4,271
PMNs
CD11a Air 10,540 ± 1,775 10,010 ± 1,771 10,107 ± 1,837 10,986 ± 2,830 11,199 ± 2,953
UFP 14,562 ± 2,749 14,161 ± 2,679 13,790 ± 2,780 13,765 ± 2,727 13,710 ± 2,652
CD11b Air 24,078 ± 2,783 26,353 ± 3,578 25,211 ± 2,533 25,199 ± 2,072 30,893 ± 4,350
UFP 23,819 ± 2,343 22,792 ± 3,224 25,376 ± 2,984 22,085 ± 2,479 22,781 ± 1,886
CD18 Air 48,861 ± 3,054 47,564 ± 3,026 45,449 ± 2,457 45,303 ± 2,719 50,312 ± 5,429
UFP 46,982 ± 2,925 44,465 ± 2,676 43,512 ± 3,174 44,599 ± 2,862 43,470 ± 3,006
CD49d Air 5,342 ± 211 5,122 ± 228 5,090 ± 162 4,805 ± 248 4,923 ± 185
UFP 5,499 ± 315 4,964 ± 212 4,887 ± 210 4,783 ± 234 4,950 ± 241
CD54 Air 5,631 ± 230 5,348 ± 236 5,234 ± 222 5,433 ± 277 5,635 ± 239 Exposure × time
UFP 6,262 ± 451 5,759 ± 453 5,604 ± 458 5,535 ± 399 5,660 ± 398 p = 0.031
CD62L Air 78,859 ± 3,812 69,825 ± 3,978 71,796 ± 3,691 72,829 ± 4,711 72,429 ± 4,184 Exposure × sex
UFP 79,315 ± 6,332 75,646 ± 6,405 70,468 ± 4,961 74,971 ± 5,500 74,541 ± 5,925 p = 0.011on PMNs increased in males but not females
(exposure–sex interaction, p = 0.011; Figure
3C,D). Expression of CD54 on PMNs
decreased, with the greatest difference from
control at 45 hr after exposure (exposure–time
interaction, p = 0.031; data not shown).
Lymphocyte subsets and activation. There
was evidence for increased activated T cells
after UFP exposure in healthy subjects. In
UPDOSE, CD25 expression on CD3+ T cells
increased in females, but not in males, early
after exposure to 25 µg/m3 UFPs (exposure–sex
interaction, p = 0.002; Figure 4A,B). In UP50,
exposure to 50 µg/m3 increased CD25 expres-
sion on T cells 0 hr after exposure (p = 0.001 by
paired t-test at 0 hr after exposure; p = 0.085 by
ANOVA; Figure 4C). There were no other
changes in lymphocyte subsets in the healthy
subjects.
In UPASTHMA, CD4+ T cells decreased
immediately after exposure to UFPs, compared
with air (exposure–time interaction, p = 0.021;
Figure 2D). There were no signiﬁcant effects
on other lymphocyte subsets or CD25 expres-
sion. However, the percentage of T-lympho-
cytes expressing the activation marker CD25
was higher in asthmatic subjects than in healthy
subjects before exposure (UPASTHMA, 33.0 ±
3.3%, vs. UPDOSE, 27.0 ± 2.5%; p = 0.04).
Overall, the data suggest that UFP expo-
sure induces activation (healthy subjects) or
sequestration (subjects with asthma) of
T-lymphocytes.
Blood leukocyte and platelet counts. In
each of the protocols involving exercise
(UPDOSE, UP50, and UPASTHMA), consis-
tent postexposure increases were seen in the
total leukocyte count and the percentage of
PMNs, with decreases in the percentage of
eosinophils and monocytes. In the UPDOSE
protocol, ANOVA showed a signiﬁcant expo-
sure–sex interaction for an effect on the per-
centage of blood monocytes (p = 0.0015). As
shown in Figure 5A,B, in females monocytes
decreased after exposure to 25 µg/m3 and did
not return to baseline at 21 hr after exposure.
This observation was conﬁrmed when mono-
cyte numbers were analyzed by ﬂow cytometry,
using light scatter and CD14 expression (over-
all effect of UFPs, p = 0.035; exposure–sex
interaction, p = 0.002). A signiﬁcant decrease
in blood basophils in females was also seen
with both UFP concentrations (exposure–sex
interaction, p = 0.015; data not shown).
Exposure to 50 µg/m3 UFPs caused small
reductions in the percentage of eosinophils,
with a larger effect in females (Figure 5C,D).
There were no signiﬁcant effects on the per-
centage of blood monocytes, PMNs, or baso-
phils in this protocol.
In subjects with asthma exposed to
10 µg/m3 UFPs, basophils decreased in both
men and women at 0 and 3.5 hr after expo-
sure to UFPs, compared with air exposure
(exposure–time interaction, p = 0.02; data not
shown). The percentage of blood eosinophils
as determined by flow cytometry decreased
0 and 3.5 hr after exposure, with greater
reductions after UFP exposure than after air
(p = 0.049).
UFP exposure did not change platelet
counts in any of the exposure protocols.
These data suggest that exposure to UFPs
with exercise causes small changes in blood
leukocyte differential counts in both healthy
and asthmatic subjects.
Discussion
The objective of these studies was to deter-
mine whether inhalation of carbon UFPs has
vascular effects in healthy subjects, and in
subjects with asthma. We postulated that
changes in blood leukocyte phenotype and
expression of adhesion molecules would serve
as a “window” on vascular inflammatory
effects after inhalation challenge. Although
the speciﬁc ﬁndings differed among the pro-
tocols, all three protocols with exercise
showed UFP-associated reductions in expres-
sion of adhesion molecules on leukocytes,
mainly ICAM-1 (CD54) and the β2 integrins
CD11b and CD18. There were significant
differences between healthy and asthmatic
subjects in leukocyte expression of adhesion
molecules, when measured before exposure
(Table 7). For example, blood monocytes
from subjects with asthma showed decreased
expression of CD11a and increased expres-
sion of CD11b, CD49d, and CD54 relative
to healthy subjects. This may reflect relative
activation or priming of circulating leukocytes
Ultrafine particles and blood leukocytes
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Table 7. Blood leukocyte marker expression at
baseline that differed between asthmatic and
healthy subjects (mean ± SE, MESF).
Healthya Asthma p-Value
Lymphocytes
CD11a 41,710 ± 1,844 14,575 ± 4,161 < 0.001
CD11b 1,460 ± 67 1,784 ± 107 0.017
CD49d 8,168 ± 335 10,486 ± 324 < 0.001
CD54 2,381 ± 69 2,964 ± 155 0.003
Monocytes
CD11a 64,155 ± 4,041 26,220 ± 5,260 < 0.001
CD11b 17,944 ± 915 25,047 ± 2,751 0.025
CD49d 13,556 ± 915 17,089 ± 642 0.005
CD54 12,314 ± 401 17,942 ± 1,065 < 0.001
PMNs
CD11a 28,358 ± 904 12,753 ± 2,276 < 0.001
CD11b 16,868 ± 1,055 24,178 ± 2,705 0.021
CD49d 7,189 ± 545 5,292 ± 282 0.007
CD62L 63,591 ± 4,614 80,656 ± 5,954 0.032
aIncludes subjects from UPREST and UPDOSE (n = 24).
Source of some immunoﬂuorescence markers differed for
UP50, resulting in changes in baseline values, so these
healthy subjects were not included.
Figure 1. Changes in monocyte expression of CD54
(ICAM-1), UPDOSE protocol. In this and following
ﬁgures, data are shown as mean ± SE changes from
baseline. Nominal UFP exposure concentrations are
shown in µg/m3. Exposure, p = 0.012.
Figure 2. Changes in leukocyte expression of adhesion molecules, UP50 protocol. (A) Monocyte expression
of CD54, females. UFP × sex, p = 0.025. (B) Monocyte expression of CD54, males. UFP × sex, p = 0.025.
(C) Monocyte expression of CD18. UFP, p = 0.0002. (D) PMN expression of CD18. UFP, p = 0.023.
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as a consequence of airway inflammation.
In subjects with asthma, inhalation of UFPs
reduced expression of CD11b on monocytes
and eosinophils (Figure 3) and reduced
CD54 expression on PMNs (Table 6).
In addition, the data suggested subtle
reductions relative to air exposure in the per-
centage of blood monocytes, eosinophils, and
basophils. There was evidence for activation of
CD4+ T-lymphocytes in healthy subjects and
transient reductions in CD4+ T-cell numbers
in asthmatic subjects. Sex interactions were
seen for some of these changes. A summary of
these ﬁndings is shown in Table 8.
The ﬁndings provide evidence that inhala-
tion of elemental carbon UFPs, with intermit-
tent exercise, causes phenotypic alterations in
blood leukocytes at concentrations as low as
approximately 10 µg/m3 or approximately 2 ×
106 particles/cm3. However, the overall nature
and direction of the changes do not suggest
increased systemic inﬂammation. This is con-
sistent with the lack of evidence for airway or
systemic inﬂammation that we have reported
previously for these studies (Pietropaoli et al.
2004a, 2004c).
The reductions in leukocyte subsets and
adhesion molecule expression seen in these stud-
ies suggest the possibility of leukocyte seques-
tration or margination in response to UFP
exposure. The relative reductions in monocyte,
basophil, and eosinophil percentages may result
from slightly prolonged transit time through the
pulmonary circulation after exposure to UFPs,
possibly as a consequence of pulmonary vaso-
constriction. The reductions in expression of the
adhesion molecules CD54, CD11b, and CD18
are consistent with this hypothesis. Blood leuko-
cytes normally marginate in the lung, requiring
several seconds to transit the pulmonary circula-
tion (Doerschuk 2003). PMNs are larger than
pulmonary capillaries and must deform in order
to transit. The integrins CD11a and CD11b are
expressed as dimers with CD18 and mediate
blood leukocyte recruitment to areas of inﬂam-
mation and injury via speciﬁc receptors on vas-
cular endothelial cells. Activation of monocytes
and PMNs increases expression of CD11b and
CD18 and decreases cell deformability through
actin polymerization (Anderson et al. 2001),
slowing transit time. Exercise increases pul-
monary blood flow and decreases leukocyte
transit time through the pulmonary circulation,
leading to mobilization of the pulmonary leuko-
cyte pool into the systemic vascular pool. Van
Eeden et al. (1999) have shown that maximal
exercise increases the blood leukocyte count and
also increases expression of CD11b on periph-
eral blood PMNs, suggesting that cells express-
ing higher levels of CD11b preferentially
marginate in the pulmonary circulation and are
“ﬂushed out” with exercise. Thus, our data are
consistent with, but do not prove, increased
retention of leukocytes expressing higher levels
of adhesion molecules in the pulmonary vascu-
lar bed in response to UFP exposure.
Pulmonary vasoconstriction in response to
UFP exposure would be expected to delay
leukocyte transit through the lung. We have
reported (Pietropaoli et al. 2004b) that, in the
UP50 protocol, UFP exposure caused reduc-
tions in the diffusing capacity for carbon
monoxide, without effects on the forced vital
capacity, consistent with reduced vascular per-
fusion or reduced ventilation/perfusion match-
ing. We also reported preliminary findings
(Pietropaoli et al. 2004a) of subtle but signiﬁ-
cant effects on systemic ﬂow-mediated vascular
dilatation, and a decrease in blood nitrate lev-
els, suggesting the vascular effects may result
from decreased nitric oxide availability. Batalha
et al. (2002) have shown pulmonary vaso-
constriction in rats exposed to concentrated
ambient ﬁne particles.
Figure 3. Changes in leukocyte expression of adhesion molecules, UPASTHMA protocol. (A) Monocyte
expression of CD11b. UFP, p = 0.029. (B) Eosinophil expression of CD11b. UFP, p = 0.015. (C) PMN expres-
sion of CD62L, females. UFP × sex, p = 0.011. (D) PMN expression of CD62L, males. UFP × sex, p = 0.011.
Figure 4. Changes in blood T-lymphocyte subsets. (A) UPDOSE protocol, percentage of CD25+ cells within
the T-cell (CD3+) gate, females. UFP × sex, p = 0.0024. (B) UPDOSE protocol, CD3+CD25+ T cells, males. UFP
× sex, p = 0.0024. (C) UP50 protocol, CD3+CD25+ T cells, all subjects. UFP × time, p = 0.085. (D) UPASTHMA
protocol, CD4+ T cells, all subjects. UFP × time, p = 0.021.
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leukocyte and their surface markers include
a) direct effects of UFPs on blood leukocytes,
reducing surface marker expression through
shedding, redistribution, or internalization;
b) indirect effects of mediators released by vas-
cular endothelium, such as nitric oxide, which
has anti-inﬂammatory properties (Lefer 1997),
reduces endothelial expression of adhesion
molecules via inhibition of nuclear factor
κB activation, and reduces monocyte adhesion
to endothelium (De Caterina et al. 1995);
c) adsorption of soluble cytokines, such as
transforming growth factor-β, onto the surface
of the particles, reducing inﬂammatory effects
(Kim et al. 2003); d) recruitment of immature
leukocytes from the bone marrow in response
to UFP inhalation, as has been suggested in
previous studies of ﬁne particle exposure (Tan
et al. 2000); and e) selective toxicity of UFPs
for activated blood leukocytes, inducing apop-
tosis of speciﬁc cell subsets.
The two protocols with exercise in healthy
subjects showed increased expression of CD25
on blood T-lymphocytes, and subjects with
asthma showed a transient reduction in CD4+
lymphocytes after UFP exposure. CD25 is the
α-chain of the IL-2 receptor; IL-2 promotes
lymphocyte proliferation. We found that lym-
phocyte CD25 expression was higher in sub-
jects with asthma than in healthy subjects,
conﬁrming previous observations that people
with asthma have a higher percentage of circu-
lating activated T-lymphocytes (Corrigan and
Kay 1990), which may explain why UFP
exposure did not increase it further in these
subjects. The rapid and transient nature of the
reduction in CD4+ T cells suggests redistri-
bution or margination of cells, as postulated
above for other blood leukocytes.
The changes in response to carbon UFP
exposure reported in these studies were gener-
ally small and would not be expected to
adversely affect healthy and mildly asthmatic
subjects similar to those studied. However,
ambient UFPs contain reactive organic species
and transition metals that may induce greater
effects than those we observed. People with
severely compromised cardiovascular status
may experience adverse effects from even small
changes in vascular homeostasis. Furthermore,
prolonged, repeated exposures may hasten the
progression of atherosclerosis, as has been sug-
gested in an epidemiology study of ﬁne parti-
cle exposure (Künzli et al. 2005).
The UFP number concentrations used in
these studies are higher than UFP background
concentrations but are relevant to episodic levels
seen in speciﬁc situations. UFPs are always pre-
sent in ambient air, with background urban lev-
els in the range of 40,000–50,000 particles/cm3
or estimated mass concentrations of 3–4 µg/m3
(Peters et al. 1997b). Episodic increases have
been documented to 300,000 particles/cm3, or
estimated to approximately 50 µg/m3 UFPs as
an hourly average (Brand et al. 1991, 1992).
Particle numbers inside a vehicle on a major
highway reached 107 particles/cm3 (Kittelson
et al. 2001), comparable with the highest con-
centrations used in our studies.
Although not speciﬁcally powered to detect
sex differences, these studies were designed to
include an analysis of sex interactions with the
effects of UFP exposure. In the UPDOSE pro-
tocol, females showed greater decreases in blood
monocytes (Figure 5A) and basophils and
greater increases lymphocyte CD25 expression
(Figure 4A) compared with males. Females also
showed decreased eosinophils in the UP50 pro-
tocol (Figure 5C). In UPASTHMA, expression
of L-selectin (CD62L) on PMNs was increased
in males (Figure 3B). It is possible that males
and females differ in their cardiovascular
responses to particle exposure. There are known
sex differences in leukocyte function and car-
diovascular responses, based in part on hor-
monal inﬂuences. For example, females have a
higher percentage of CD4+ T cells and a higher
CD4+:CD8+ ratio than do males. Stimulated
blood monocytes from females produce more
prostaglandin E2 (Leslie and Dubey 1994) and
less tumor necrosis factor-α and IL-6 (Schwarz
et al. 2000) than those from males. There are
also sex differences in endothelial function and
antioxidant defenses that may affect vascular
response to inhaled challenge. However, we do
not feel that these studies have convincingly
established or excluded signiﬁcant sex differ-
ences in responses to carbon UFPs.
There are limitations to this study. First,
our particles were laboratory-generated elemen-
tal carbon, without signiﬁcant organic species,
metals, oxides, nitrates, or sulfates. The ﬁndings
of these studies may not be representative of
Ultrafine particles and blood leukocytes
Environmental Health Perspectives • VOLUME 114 | NUMBER 1 | January 2006 57
Table 8. Summary of UFP exposure effects.
Lymphocyte subsets
Protocol Adhesion molecules and activation Leukocyte counts
UPREST (n = 12) No convincing effects (see text) No effects No effects
UPDOSE (n= 12) Decreased monocyte CD54 Increased CD25+ Decreased monocytes
Decreased PMN  T cells (females) and basophils (females)
CD49d (males)
UP50 (n = 16) Decreased monocyte CD18 and Increased CD25+ Decreased eosinophils
CD54 (males) T cells
Decreased PMN CD18 and
increased CD11a
UPASTHMA (n= 16) Decreased monocyte CD11b Decreased CD4+ Decreased eosinophils
Decreased PMN CD54 T cells and basophils
and increased CD62L (males)
Decreased eosinophil CD11b
Figure 5. Changes in percentage of blood leukocytes with exposure to UFPs. (A) UPDOSE protocol, mono-
cytes, females. UFP × sex, p = 0.0015. (B) UPDOSE protocol, monocytes, males. UFP × sex, p = 0.0015.
(C) UP50 protocol, eosinophils, females. UFP × time × sex, p = 0.01. (D) UP50 protocol, eosinophils, males.
UFP × time × sex, p = 0.01.
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UFP 50 µg/m3exposure to ambient particles, which are a mix
of ultraﬁne, ﬁne, and coarse particles, with reac-
tive organic species, metals, and oxidants in
addition to elemental carbon. These and other
chemical species may enhance pulmonary and
vascular effects. Second, each protocol involved
a fairly large number of measurements, and
some statistically signiﬁcant changes may have
been chance related. Our approach was to con-
sider results that showed consistency within and
across protocols and to discount ﬁndings of iso-
lated statistical signiﬁcance that were not sup-
ported by other data. The observations of UFP
effects on leukocyte distribution and surface
marker expression meet those criteria.
Conclusions
Overall, the ﬁndings from these studies pro-
vide evidence that inhalation of carbon UFPs,
with exercise, reduces peripheral blood mono-
cytes, eosinophils, and basophils and reduces
expression of some adhesion molecules on
monocytes and PMNs. When considered in
light of other evidence, the leukocyte changes
may be a consequence of endothelial activa-
tion or vasoconstriction in the pulmonary
and/or systemic circulation.
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